Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
University of Chicago
Regeneron Pharmaceuticals
Genmab
Genmab
Genmab
Allogene Therapeutics
Fred Hutchinson Cancer Center
Lyell Immunopharma, Inc.
Novartis
Essen Biotech
Mayo Clinic
Regeneron Pharmaceuticals
University of Michigan Rogel Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Celgene
Fred Hutchinson Cancer Center
Gilead Sciences
M.D. Anderson Cancer Center
Celgene
Sana Biotechnology
Massachusetts General Hospital
University of Arizona
Case Comprehensive Cancer Center
Celgene
Thomas Jefferson University
Gilead Sciences
City of Hope Medical Center
University of Maryland, Baltimore
Jonsson Comprehensive Cancer Center
Universität des Saarlandes
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Adicet Therapeutics
Peking University Cancer Hospital & Institute
City of Hope Medical Center
Janssen Research & Development, LLC
City of Hope Medical Center
University of Liverpool
Synthekine
Fred Hutchinson Cancer Center
Mayo Clinic
Tianjin Medical University Cancer Institute and Hospital
MEI Pharma, Inc.